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Efficacy of the 1-year (13-cycle) segesterone acetate and 
ethinylestradiol contraceptive vaginal system: results of 
two multicentre, open-label, single-arm, phase 3 trials
David F Archer, Ruth B Merkatz, Luis Bahamondes, Carolyn L Westhoff, Philip Darney, Dan Apter, Jeffrey T Jensen, Vivian Brache, Anita L Nelson, 
Erika Banks, György Bártfai, David J Portman, Marlena Plagianos, Clint Dart, Narender Kumar, George W Creasy, Regine Sitruk-Ware, Diana L Blithe
Summary
Background A ring-shaped, contraceptive vaginal system designed to last 1 year (13 cycles) delivers an average of 
0·15 mg segesterone acetate and 0·013 mg ethinylestradiol per day. We evaluated the efficacy of this contraceptive 
vaginal system and return to menses or pregnancy after use.
Methods In two identically designed, multicentre, open-label, single-arm, phase 3 trials (one at 15 US academic and 
community sites and one at 12 US and international academic and community sites), participants followed a 21-days-
in, 7-days-out segesterone acetate and ethinylestradiol contraceptive vaginal system schedule for up to 13 cycles. 
Participants were healthy, sexually active, non-pregnant, non-sterilised women aged 18–40 years. Women were 
cautioned that any removals during the 21 days of cyclic use should not exceed 2 h, and used daily paper diaries to 
record vaginal system use. Consistent with regulatory requirements for contraceptives, we calculated the Pearl Index 
for women aged 35 years and younger, excluding adjunctive contraception cycles, as the primary efficacy outcome 
measure. We also did intention-to-treat Kaplan-Meier life table analyses and followed up women who did not use 
hormonal contraceptives or desired pregnancy after study completion for 6 months for return to menses or pregnancy. 
The trials are registered with ClinicalTrials.gov, numbers NCT00455156 and NCT00263341.
Findings Between Dec 19, 2006, and Oct 9, 2009, at the 15 US sites, and between Nov 1, 2006, and July 2, 2009, at the 
12 US and international sites we enrolled 2278 women. Our overall efficacy analysis included 2265 participants 
(1130 in the US study and 1135 in the international study) and 1303 (57·5%) participants completed up to 13 cycles. 
The Pearl Index for the primary efficacy group was 2·98 (95% CI 2·13−4·06) per 100 woman-years, and was well 
within the range indicative of efficacy for a contraceptive under a woman’s control. The Kaplan-Meier analysis revealed 
the contraceptive vaginal system was 97·5% effective, which provided further evidence of efficacy. Pregnancy 
occurrence was similar across cycles. All 290 follow-up participants reported return to menses or became pregnant 
(24 [63%] of 38 women who desired pregnancy) within 6 months.
Interpretation The segesterone acetate and ethinylestradiol contraceptive vaginal system is an effective contraceptive 
for 13 consecutive cycles of use. This new product adds to the contraceptive method mix and the 1-year duration of 
use means that women do not need to return to the clinic or pharmacy for refills every few months.
Funding Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes 
of Health, the US Agency for International Development, and the WHO Reproductive Health Research Department.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
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Introduction
Despite global efforts to support family planning goals of 
women and families, over 200 million women and girls 
in low-income and middle-income countries who want to 
delay or avoid pregnancy do not have access to modern 
contraceptive methods that they find acceptable.1,2 An 
unmet contraceptive need persists in the USA, where 
45% of all pregnancies are unintended.3 To address 
this need, the Population Council developed a 1-year 
(13-cycle), ring-shaped, contraceptive vaginal system that 
is under a woman’s control.
Proof of concept for development of a vaginal 
contraceptive was first shown in the late 1960s by Mishell 
and Lumkin.4 The vaginal mucosa is efficient for systemic 
absorption of contraceptive steroids, including orally 
inactive steroids.4 The contraceptive vaginal ring delivers 
a novel progestin, segesterone acetate—also known as 
Nestorone—with ethinylestradiol, an approved component 
of many oral contraceptives. Segesterone acetate is a 
19-norprogesterone derivative and a new chemical entity 
for which there are considerable non-clinical5,6 and clinical 
trial data.7,8 This drug is not absorbed orally but is effective 
when administered via non-oral routes.5,6 In the contra-
ceptive vaginal system, the two hormones are delivered via 
a silicone-based, soft ring containing a segesterone acetate 
and ethinylestradiol core and a segesterone-acetate-only 
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core (a total of 103 mg segesterone acetate and 17·4 mg 
ethinylestradiol). After an initial burst from steroid 
accumulation on the ring surface, drug is released 
constantly for consistent blood levels (an average daily 
dose of 0·15 mg segesterone acetate and 0·013 mg 
ethinylestradiol),9 in contrast to daily steroid fluctuations 
with oral contraceptives.10
An open-label, pharmacokinetic study of the segest-
erone acetate and ethinylestradiol contraceptive vaginal 
system in 39 women verified rapid absorption of both 
steroids through the vaginal mucosa after insertion, with 
steady-state, systemic levels of segesterone acetate and 
ethinylestradiol achieved by day 4 of use.11 Mean serum 
segesterone acetate and ethinyl estradiol concentrations 
peak immediately after the first contra ceptive vaginal 
system insertion in cycle 1 and decline rapidly to a steady 
state by 96 h. Peak and steady state levels fall modestly in 
subsequent cycles.
The segesterone acetate and ethinylestradiol contra-
ceptive vaginal system has several potential advantages for 
women across diverse settings. The cyclic regimen of 
21 days in and 7 days out provides regular withdrawal 
bleeds, a pattern familiar to and desirable for many 
women.12 Using the same contraceptive vaginal system for 
thirteen 28-day cycles (1 year) enhances convenience and 
addresses a common access issue that can be a factor in 
unintended pregnancies (difficulties returning to health-
care facilities or pharmacies for refills or new prescriptions 
for hormonal contraceptives requiring timely use). Ad-
ditionally, the segesterone acetate and ethinylestradiol 
contraceptive vaginal system does not require refrigeration 
before dispensing or during non-use, facilitating storage 
and distribution, an access element affecting providers 
and women across many regions.
Here, we present data from two 13-cycle, open-label 
trials designed to assess the contraceptive efficacy of the 
segesterone acetate and ethinylestradiol contraceptive 
vaginal system and document return to menses or 
pregnancy after use following study completion.
Methods
Study design and participants
Consistent with US Food and Drug Administration 
(FDA) guidance, contraceptive development for a new 
chemical entity should include two pivotal, open-label, 
phase 3 studies. Hence, we conducted two studies with 
matching protocols and combined the results to show 
efficacy. One study was done by the Eunice Kennedy 
Shriver National Institute of Child Health and Human 
Development (NICHD) Contra ceptive Clinical Trial 
Network (CCTN) at 15 US academic and community 
sites and the other (international and US) study was 
done by the Population Council (the study sponsor) at 
12 academic and community sites including five in the 
USA, and one each in Brazil, Chile, Dominican Republic, 
Finland, Hungary, Sweden, and Australia.
Study protocols were approved by the Institutional 
Review Boards (IRBs) of the Population Council and the 
NICHD Coordinating Center, and the IRB or Ethical 
Committee at each site. An independent Data Safety 
Monitoring Board (DSMB) established by the NICHD 
regularly reviewed pregnancy and safety data. All 
potential participants provided written informed consent 
before screening and any study procedures.
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Evidence before this study
Although several contraceptive methods are available, 
including combined hormonal contraceptives, many women 
and girls worldwide do not have access to modern 
contraceptives that address changing needs over their 
reproductive life span, and many unintended pregnancies still 
occur. To address this need, the Population Council developed 
a ring-shaped, contraceptive vaginal system containing 
segesterone acetate and ethinylestradiol that is under a 
woman’s control, releases a consistent level of hormones over 
1 year of cyclic use, and does not require refrigeration during 
periods of non-use. Results of pharmacokinetic and phase 2 
studies showed absorption of segesterone acetate and 
ethinylestradiol through the vaginal mucosa with serum levels 
that were adequate for ovulation suppression and pregnancy 
prevention. Data from these studies also showed that women 
were able to use the product without difficulty and found it 
acceptable. Based on the positive results from these earlier 
studies and the potential of the product to add to the method 
mix of safe, effective, and acceptable contraceptives, the 
Population Council pursued full development of the 
segesterone acetate and ethinylestradiol contraceptive 
vaginal system.
Added value of this study
Results of our pivotal phase 3 studies showed the efficacy and 
safety of the segesterone acetate and ethinylestradiol 
contraceptive vaginal system, with an overall Pearl Index 
of 2·98 and a contraceptive efficacy rate of 97·5% based on a 
life table analysis. These results and accompanying data were 
crucial components of a US Food and Drug Administration 
review leading to regulatory approval in August, 2018. Since 
this study included seven non-US sites, these data can be 
considered applicable to global populations.
Implications of all the available evidence
The segesterone acetate and ethinylestradiol contraceptive 
vaginal system is a new, safe, and effective combined hormonal 
contraceptive that is under a woman’s control. The fact that 
one contraceptive vaginal system is effective for a full year of 
cyclic use and does not require refrigeration during periods of 
non-use might facilitate contraceptive accessibility and help to 
address a global unmet contraceptive need.
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Participants were healthy, sexually active, non-pregnant, 
non-sterilised women aged 18–40 years, who did not 
intend to become pregnant over the next 13 months. 
Participants also had to have an intact uterus and both 
ovaries, have a history of regular menstrual cycles that 
usually occurred every 28 days (±7 days) when not using 
hormonal contraception (if post-partum or post-abortal, 
participants had to have a history of regular menstrual 
cycles of 21–35 days and resumption of at least one cycle 
with a cycle length consistent with past cycles), be willing 
to discontinue their current contraceptive method to 
participate in the study, and, in the opinion of the 
investigator, be able to comply with the protocol (eg, live 
within the clinic catchment area or within a reasonable 
distance of the clinic). Exclusion criteria were known 
hypersensitivity to oestrogens or progestins; known 
hypersensitivity to silicone rubber; known or suspected 
pregnancy; history of infertility of longer than 1 year in the 
woman or her male partner; history of vasectomy or 
sterility in male partner; tubal ligation (sterilisation) in 
women; undiagnosed abnormal genital bleeding; and 
undiagnosed vaginal discharge or vaginal lesions or 
abnormalities. Participants diagnosed at screening with a 
chlamydia or gonococcus infection could be included 
in the trial after treatment; partner treatment was 
also recommended. Investigators determined whether 
participants were at high risk for reinfection (eg, because 
of multiple sex partners or an untreated partner) and 
whether such participants could be included. In 
accordance with primary investigator or medical designee 
assessment and local standards of practice, women with a 
history of genital herpes could be included if outbreaks 
were infrequent. Further exclusion criteria were a history 
of pelvic inflammatory disease since last pregnancy 
episode; a history of toxic shock syndrome, and in 
accordance with the Bethesda system of classification, 
women with a current abnormal Pap smear suggestive of 
high-grade precancerous lesion(s), including high-grade 
squamous intraepithelial lesions, were excluded. Women 
with low-grade squamous intraepithelial lesions or 
atypical squamous cells of undetermined significance or 
who were high-risk and humam papillomavirus-positive 
could participate if further evaluated with colposcopy and 
biopsy and no evidence of a lesion with severity greater 
than cervical intraepithelial neoplasia (CIN) I was present 
or endocervical curettage was negative. Women with a 
biopsy finding of CIN I were followed up for this finding 
per standard of care; and women were excluded if 
treatment was indicated. In accordance with other Pap 
classification systems, women with high grade dysplasia 
were excluded, women with low grade dysplasia or CIN I 
interpretation on Pap smear could participate if further 
evaluated with colposcopy and, as needed, biopsy with 
endocervical curettage, women could participate if 
colposcopy findings were negative, provided there was 
appropriate follow-up in accordance with local standards 
of care, and women whose colposcopy results indicated 
need for biopsy could participate as long as biopsy results 
indicated there was no lesion with a severity greater than 
CIN I and endocervical curettage results were negative. 
Additional exclusion criteria were cystoceles or rectoceles 
or another anatomical abnormality that would preclude 
use of a vaginal ring; women planning to undergo major 
surgery; smoking in women who were 35 years and older 
or who would be 35 years of age during the course of the 
trial (women <35 years who smoked 15 cigarettes or more 
per day were evaluated by the primary investigator for 
inclusion based on risk factors that would increase their 
risk for cardiovascular disease and thromboembolism, eg, 
lipid levels, glucose level, blood pressure, body-mass index 
[BMI], family history of cardiovascular disease at a young 
age); breastfeeding; current or previous thrombophlebitis 
or thromboembolic disorders; history of venous throm-
bosis or embolism in a first-degree relative younger than 
55 years of age suggesting a familial defect in the blood 
coagulation system, which in the opinion of the primary 
investigator, suggested use of a hormonal contraceptive 
could pose a significant risk; cerebrovascular or cardio-
vascular disease; history of retinal vascular lesions, or 
unexplained partial or complete loss of vision; known or 
suspected carcinoma of the breast; carcinoma of the 
endometrium or other known or suspected oestrogen-
dependent neoplasia; previous history of any other 
carcinoma unless in remission for more than 5 years; 
current or history of medically diagnosed severe 
depression, which, in the opinion of the investigator, 
could be exacerbated by use of a hormonal contraceptive; 
headaches with focal neurological symptoms; severe 
constipation; history of cholestatic jaundice of pregnancy 
or jaundice with previous steroid use; benign or malignant 
liver tumours or active liver disease; diastolic blood 
pressure greater than 85 mm Hg or systolic blood pressure 
greater than 135 mm Hg after 5–10 min rest; known or 
suspected alcoholism or drug abuse; abnormal serum 
chemistry values according to the physician’s judgment; 
partici pation in another clinical trial involving an 
investigational drug within the last 30 days (before 
screening); BMI greater than 29 kg/m²; use of liver 
enzyme inducers on a regular basis; use of monthly 
injectable contraceptives unless suspended 2 months 
before initiation of treatment; use of medroxyprogesterone 
acetate unless suspended 6 months before treatment; 
current use of implanted hormonal contraceptives 
(participants using this method who requested removal 
for reasons unrelated to the purpose of enrolment in this 
study could be considered for participation); current use 
of a non-hormonal intrauterine device (participants with 
intra uterine devices who requested removal for reasons 
unrelated to the purpose of enrolment in this study could 
be considered for participation); known HIV infection; 
and women at high risk of contracting HIV, for example, 
women with multiple sex partners who needed to use 
condoms consistently or injection drug users. If women 
enrolled in the study did use condoms to protect against 
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sexually transmitted infections, they were instructed that 
this occasional use should be with non-nonoxynyl-9 
containing condoms and they should record condom 
use in their diaries. Women found to have a sexually 
transmitted infection at screening were treated before 
inclusion in the study (with the exception of those infected 
with HIV). Women were not enrolled if they chronically 
used concomitant medications known to induce cyto-
chrome P450 liver enzymes, especially cytochrome 
P450 3A4. 
6 months after the trial commenced, the DSMB 
recommended exclusion of women with a BMI greater 
than 29·0 kg/m² rather than exclusion based on 
weight because of the well characterised risk of venous 
thromboembolism in obese women13 and the occurrence 
of non-fatal venous thromboembolisms in two participants 
with BMI greater than 29·0 kg/m² reported early in the 
study.
Participants were recruited to the trial through IRB-
approved local advertising.
Procedures
Participants were screened after expressing interest 
and consenting to trial involvement. Screening involved 
clinical tests, physical examination, including a gynaeco-
logical examination, and obtaining a medical history, 
including history of pregnancy. After screening, all 
eligible participants began the study identically, regard-
less of their previous contraceptive method use. 
Contraceptive vaginal system use was initiated at the 
baseline visit, which occurred between menstrual days 2 
and 5, and after a negative urine pregnancy test. Urine 
pregnancy tests were repeated at all subsequent visits 
(cycles 3, 6, 9, and 13), and at the final study termination 
visit (1–2 weeks after cycle 13). Women who discontinued 
the study early had pregnancy tests at their last study visit.
The day of contraceptive vaginal system insertion 
became day 1 of the first treatment cycle. Site staff 
counselled participants on proper use of the contraceptive 
vaginal system, provided written instructions that 
outlined the 21-days-in and 7-days-out regimen, and 
reinforced directions about keeping the contraceptive 
vaginal system in place continuously during the first 
21 days of each cycle. Women were cautioned that any 
removals of the contraceptive vaginal system during the 
21 days of cyclic use should not exceed 2 h. These 
instructions were based on early work with segesterone 
acetate implants, which suggested that ovulation was 
likely when segesterone acetate serum levels drop below 
100 pmol/L,8,14 and pharmacokinetic data confirming 
that segesterone acetate levels decline rapidly with 
contraceptive vaginal system removal for longer than 
2 h.11 Correct use of the contraceptive vaginal system was 
reviewed at all subsequent visits, and during telephone 
contact that occurred midway between scheduled visits. 
Participants having difficulty following these instructions 
were counselled at additional timepoints. A contraceptive 
vaginal system could be replaced if accidentally lost.
Participants used a daily diary card during the study to 
record dates when the contraceptive vaginal system was 
in or out of place, any duration of removal longer than 
2 h during a period of contraceptive vaginal system use, 
and any bleeding or spotting during each 28-day cycle. 
Participants also noted dates when they were sexually 
active, used condoms or other contraceptives, including 
emergency contraceptive pills, experienced expulsions 
(complete or partial) or any other problems with the 
contraceptive vaginal system, any health issues, and use 
of other medications. Study personnel reviewed diary 
entries at all participant visits. Participants removed the 
contraceptive vaginal system for the last time on day 22 
of cycle 13.
Participants not continuing hormonal contraception at 
study end were followed up for 6 months to document 
spontaneous return to menses. Women who desired 
pregnancy were followed up for pregnancy occurrence 
up to 6 months. All women in the follow-up study 
received urine pregnancy test kits at their last study 
visits, with instructions to test within 2 to 3 weeks after 
that visit, and monthly thereafter, if they had no bleeding 
or had pregnancy symptoms. Participants were contacted 
every 2 months to determine if they had resumed 
spontaneous menses or had become pregnant. Patients 
were asked to return to the study site if the pregnancy 
test was positive for pregnancy confirmation and were 
referred for prenatal care as required.
Outcomes
The primary efficacy endpoint was the Pearl Index for 
women in the efficacy population who were aged 35 years 
or younger. The Pearl Index is considered a standard 
measure for determining contraceptive efficacy and 
reflects the incidence of pregnancy per 100 woman-years. 
The acceptable range of Pearl Index efficacy includes 
values where the upper boundary of the 95% CI is less 
than 5. We analysed an intention-to-treat Kaplan-Meier 
life table as a secondary efficacy outcome to evaluate 
the cumulative probability of pregnancy by cycle. 
Adverse events, physical examinations, and laboratory 
assessments were also done and have been reported 
elsewhere.9
Statistical analysis
We based the sample size on FDA recommendations and 
European Medicines Agency harmonisation guidelines 
that specify 20 000 treatment cycles of contraceptive 
vaginal system exposure with at least 400 women 
completing 1 year of treatment for contraceptives that 
contain a new chemical entity. The sample size for each 
phase 3 trial was established at around 1200 women, 
for a total of 2400 women, and, assuming that only 
45% to 55% of participants would complete 1 year of 
contraceptive vaginal system use, with an exposure of 
9000 to 11 000 cycles per study. Consistent with regulatory 
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guidance, we planned to combine efficacy data from the 
two trials to show contraceptive efficacy.
All participants who documented contraceptive vaginal 
system use in diaries after initiation of study participation 
(except for cycles occurring after pregnancy or during 
the 6-month follow-up) were included in the efficacy 
population. The Pearl Index was calculated as (total 
number of on-treatment pregnancies ÷ number of on-
treatment cycles) × 1300. For the numerator of the Pearl 
Index calculation, we included all pregnancies that 
occurred during any of 13 cycles, provided the participant’s 
estimated date of conception confirmed that the pregnancy 
occurred after onset of contraceptive vaginal system use 
or within 7 days after the participant’s final use. Site 
investigators confirmed each pregnancy and the study 
sponsor reviewed all pregnancy data. We calculated the 
estimated conception date from one of the following 
(if available) in this order: gestational age as determined 
by ultrasound or quantitative β-human chorionic 
gonadotropin (if no ultrasound), estimated date of delivery 
as entered into the obstetric record, or date of last menses.
For the denominator of the Pearl Index calculation, 
we counted all treatment cycles, regardless of diary 
documentation of coitus, except those cycles in which 
participants recorded or reported use of adjunctive 
contraception and those cycles that occurred after a 
conception. We calculated 95% CIs with a Poisson 
distribution and exact confidence limits.
We also analysed the Pearl Index among subgroups 
within the entire efficacy population. We analysed the 
Pearl Index in accordance with treatment adherence 
defined as participants’ diary data indicating continuous 
contraceptive vaginal system use for 21 days versus ring 
removal for more than 2 h during use in any cycle. 
Additionally, we calculated a Pearl Index for subgroups 
based on age, race, ethnicity, geographical region, and 
parity. For modelling purposes, we combined race into 
three categories (only black, only white, and other 
[including mixed]).
On the basis of the range of pregnancy rates for these 
subgroups, we did a post-hoc analysis to explore the 
effect of a participant’s desire to have children after they 
completed the study. We used the efficacy population for 
this analysis, which was based on participant responses 
to the screening question, “Do you wish to have children 
after the study is over?” Potential answers were “yes”, 
“no”, or “unsure”. We used Poisson regression modelling 
to examine the association between select baseline 
characteristics (ethnicity, race, age group, parity, and 
geographical location) and pregnancy, adjusted by 
participants’ desire to have children. Baseline charac-
teristics were selected a priori and tested in separate 
models that adjusted for that characteristic and the desire 
for children after the study.
For the Kaplan-Meier survival analysis, we followed all 
participants until they either had an outcome of 
pregnancy or were censored at the time of their last 
follow-up. The unit of time in our analysis was the cycle, 
with pregnancies recorded by cycle of conception. Unlike 
the Pearl Index calculation, cycles based on use of 
adjunctive contraception were not excluded.
We calculated the proportion of participants in the 
return to menses or pregnancy follow-up cohort who had 
a spontaneous menses at least 18 days after their final 
contraceptive vaginal system removal or became 
pregnant within 6 months, respectively.
Data for the efficacy analyses were finalised as SAS 
version 5 transport datasets. Statistical analyses and 
displays were created with SAS version 9.2 or later, and 
the life table analysis was done with SAS PROC LIFETEST. 
The trials are registered with ClinicalTrials.gov, numbers 
NCT00455156 and NCT00263341.
Figure 1: Trial profile
*All contraceptive vaginal systems expired by Dec 31, 2008, and subjects were 
required to discontinue treatment at that time.
962 discontinued early
 54 pregnancies
 40 became pregnant during or within 7 days 
of contraceptive vaginal system use
 14 became pregnant >7 days after contraceptive 
vaginal system use
 278 adverse events
 214 lost to follow-up
 191 withdrew consent
 89 personal problems
 57 relocation
 21 not sexually active
 13 planning pregnancy
 8 widowed, divorced, or separated
 2 medical problems
 1 mood change
 146 eligibility changed
 138 data safety monitoring board recommendations  
regarding body-mass index
 6 protocol violations determined after enrolment
 1 sponsor-modified diabetes eligibility
 1 to begin an excluded medication
 45 compliance
 33 repeated expulsions
 1 other
1303 completed the study
 941 completed at least 13 cycles
 362 completed fewer than 13 cycles*
13 excluded from efficacy analysis
 12 enrolled at more than one site
 1 did not contribute any cycles for analysis
1041 not enrolled
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Role of the funding source
The NICHD was involved in the conduct of the study. 
The US Agency for International Development (USAID) 
and WHO had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
Between Dec 19, 2006, and Oct 9, 2009, at the 15 US sites 
in the NICHD CCTN study, and between Nov 1, 2006, 
and July 2, 2009, at the 12 (international) sites in 
the Population Council study we enrolled 2278 women 
(figure 1). Although 362 participants did not complete all 
13 cycles, some of these participants were enrolled within 
6 months of drug expiration and their participation was 
limited to 6 months by design. Our overall efficacy 
analysis included 2265 participants (1130 in the US study 
and 1135 in the international study; appendix p 2) and 
1303 (57·5%) participants completed up to 13 cycles 
(figure 1). 278 (12·3%) of 2265 women discontinued the 
study early because of adverse events considered related 
to treatment and 214 (9·4%) were lost to follow-up 
(figure 1). The median follow-up time was 11 cycles 
(IQR 6–13).
Mean age was 26·7 years (SD 5·1; range 18–40) with 
1586 (70·0%) of 2265 participants ranging in age from 
20 to 29 years (table 1; appendix p 2). BMI was greater 
than 20 kg/m² but no more than 27 kg/m² in 1561 (68·9%) 
of 2265 participants. 1739 (76·8%) participants identified 
as white, and 651 (28·7%) identified their ethnicity as 
Hispanic or Latina.
The Pearl Index for the primary efficacy group was 
2·98 (95% CI 2·13–4·06) per 100 woman-years (table 2), 
which is well within the range indicative of efficacy for a 
contraceptive under a woman’s control. This calculation 
was based on 40 pregnancies that occurred in participants 
who were aged 35 years or younger and became pregnant 
during or within 7 days of last contraceptive vaginal 
system use. In 33 of these pregnancies, the study 
investigators made the diagnosis and dated the preg-
nancies by ultrasound examination. The remaining 
pregnancies were confirmed and dated by serum 
β-human chorionic gonadotropin or participants’ self-
report of their last menstrual period. The number of 
cycles used in the primary Pearl Index calculation was 
based on 2111 women aged 35 years or younger who 
contributed 17 427 cycles of use. We removed 1978 cycles 
from the Pearl Index calculation because of use of 
adjunctive contraception.
The Pearl Index was 2·10 (95% CI 1·37–3·06) for 
women who did not record any contraceptive vaginal 
system removals for longer than 2 h during the 21-day 
periods of cyclic use compared with 5·89 (3·46–9·27) 
for women who recorded contraceptive vaginal system 
removal with duration longer than 2 h (table 2). The 
See Online for appendix
Participants (n=2265)






BMI (kg/m²) 24·0 (3·6)
≤20 248 (10·9%)
>20 to ≤25 1231 (54·3%)
>25 to ≤27 330 (14·6%)






American Indian or Native Alaskan 27 (1·2%)
Native Hawaiian or Pacific Islander 15 (0·7%)
Other or unknown 114 (5·0%)
Ethnicity
Hispanic or Latina 651 (28·7%)
Non-Hispanic or non-Latina 1614 (71·3%)
Marital status






College degree or higher 948 (41·9%)
Some college 751 (33·2%)
High school diploma or equivalent 419 (18·5%)
Less than high school 147 (6·5%)
Parity >0 793 (35·0%)





Never smoked 1590 (70·2%)
Former smoker 331 (14·6%)
Current smoker 343 (15·1%)
Unknown 1 (<0·1%)
Alcohol use history
Never drank 584 (25·8%)
Former drinker 106 (4·7%)
Current drinker 1575 (69·5%)
Data are mean (SD) or n (%). BMI=body-mass index. *Multiple races allowed 
per participant.
Table 1: Demographic and baseline characteristics
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Cycles Pearl Index (95% CI)*
Primary endpoint
Age ≤35 years (primary endpoint) 2111 40 17 427 2·98 (2·13–4·06)
Intention-to-treat subgroup analyses (n=2265)†
Age (years)
18–19 140 7 1117 8·15 (3·50–15·8)
20–24 842 22 6773 4·22 (2·69–6·24)
25–29 744 8 6298 1·65 (0·75–3·07)
30–35 385 3 3239 1·20 (0·30–3·12)
≥36 154 1 1318 0·99 (0·06–4·34)
Body-mass index (kg/m²)
≤29 2065 39 17 763 2·85 (2·05–3·85)
>29 200 2 982 2·65 (0·44–8·18)
Race
Only black 319 11 2009 7·12 (3·70–12·2)
Only white 1613 19 13 983 1·77 (1·09–2·68)
Other or unknown (including 
mixed)
333 11 2753 5·19 (2·70–8·90)
Ethnicity
Hispanic 651 27 5809 6·04 (4·04–8·62)
Non-Hispanic 1614 14 12 936 1·41 (0·79–2·28)
Site
US 1519 26 11 766 2·87 (1·91–4·12)
Non-US 746 15 6979 2·79 (1·61–4·46)
European 309 1 2764 0·47 (0·03–2·07)
Non-European 1956 40 15 981 3·25 (2·35–4·37)
Parity
0 1472 14 12 280 1·48 (0·83–2·40)
Parity >0 793 27 6465 5·43 (3·63–7·74)
Education
Grade school 147 8 1224 8·50 (3·88–15·8)
High school graduate 419 13 3531 4·79 (2·63–7·88)
Some college 751 11 5747 2·49 (1·29–4·26)
College graduate or more 948 9 8243 1·42 (0·68–2·56)
Adherence
Contraceptive vaginal system 
never removed temporarily when 
scheduled to be in*
1706 24 14 843 2·10 (1·37–3·06)
Contraceptive vaginal system 
removed at least once temporarily 
when scheduled to be in*
421 16 3530 5·89 (3·46–9·27)
Data are n, unless otherwise indicated. *Subject diary cards were used to determine if the contraceptive vaginal 
system was removed temporarily (between 2 h and 23 h) on a day when the system was scheduled to be in. Some 
subjects did not return diary cards, and thus could not be grouped by temporary system removal; thus, the 
numbers of pregnancies and cycles do not sum to the total number of participants. †41 pregnancies included in 
these analyses.
Table 2: Pearl Indices for primary endpoint and other subgroups
Pearl Index was highest (8·15, 95% CI 3·50–15·8) 
among the youngest women (aged 18−19 years) and 
decreased as age increased, with a Pearl Index of 0·99 
(95% CI 0·06–4·34) among women older than 35 years. 
The Pearl Index was not influenced by BMI. Women 
who reported their race as only white had a Pearl Index 
of 1·77 (1·09–2·68), women who reported their race as 
only black had a Pearl Index of 7·12 (3·70–12·2), and 
women who reported their race as other, including 
mixed race or unknown, had a Pearl Index of 5·19 
(2·70–8·90). Hispanic women had a Pearl Index of 6·04 
(4·04–8·62) and non-Hispanic women had a Pearl 
Index of 1·41 (0·79–2·28). Women from the European 
sites had a Pearl Index of 0·47 (0·03–2·07), whereas 
women from non-European sites had a Pearl Index of 
3·25 (2·35–4·37). The nulliparous subgroup had a Pearl 
Index of 1·48 (0·83–2·40), whereas the subgroup of 
women with a parity of one or more had a Pearl Index of 
5·43 (3·63–7·74).
On the basis of a post-hoc analysis evaluating the effect 
of participants’ desire to have children after they 
completed the study, there were no Pearl Index dif-
ferences across the three response categories (yes, no, or 
unsure) for desiring children (data not shown). The 
desire for children was significantly higher among non-
parous women, but their overall pregnancy rate was 
significantly lower compared with parous women (data 
not shown). However, after adjusting for desire for more 
children, black women were more than twice as likely to 
become pregnant during the trial than were white 
women, and Hispanic women desiring pregnancy were 
almost five times more likely to become pregnant during 
the study than were non-Hispanic women (table 3). 
Among all women in the study, those who did not have 
children (nulliparous subgroup) were significantly more 
likely to desire children after the study (p<0·0001) and 
were significantly less likely to become pregnant during 
the study (Pearl Index for nulliparous women 1·48, 
95% CI 0·83–2·40, vs 5·43, 3·63–7·74 for women with 
one or more children). Therefore, for women who did 
not have children, there was an inverse association 
between desire to have children and becoming pregnant 
during the study.
The Kaplan-Meier life table estimate of the cumulative 
probability of not becoming pregnant during or within 
7 days of last contraceptive vaginal system use was 0·9745 
(95% CI 0·9649–0·9814; table 4; figure 2).
290 participants entered the 6-month follow-up for 
return to menses or pregnancy—147 from the US study 
and 143 from the international study. All participants in 
this follow-up study reported return to normal menses 
more than 18 days after last contraceptive vaginal system 
use or pregnancy. Pregnancy was reported within 
6 months of exiting the study in 24 (63·2%) 
of 38 participants from the group who desired pregnancy.
Adverse events most frequently reported by women 
using the contraceptive vaginal system included 
Pearl Index ratio 
(95% CI)
p value
Black vs white race 2·25 (1·09–4·62) 0·027
Hispanic vs non-Hispanic ethnicity 4·81 (1·53–15·13) 0·0076
Table 3: Exploratory analysis evaluating the effect of desire for children 
after the study on pregnancy rate by race and ethnicity
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head ache, nausea, vaginal discharge or vulvovaginal 
mycotic infection, and abdominal pain. Few (<1·5%) 
women discontinued use of the contraceptive vaginal 
system because of these complaints. Four (0·2%) women 
had venous thromboembolism, three of whom had risk 
factors for thrombosis (one with factor V Leiden mutation 
and two with BMI >29·0 kg/m²).9
Discussion
The segesterone acetate and ethinylestradiol contra-
ceptive vaginal system provides user-controlled, rever-
sible, hormonal contraception in a convenient, novel 
contraceptive vaginal system that can be reused for a full 
year. The results from our two pivotal phase 3 studies 
established a Pearl Index of 2·98 (95% CI 2·13–4·06), 
which is consistent with that of other more recently 
approved combined hormonal contraceptives under a 
woman’s control.15–18 Our intention-to-treat life table 
analysis indicating that the contraceptive vaginal system 
is 97·5% effective in preventing pregnancy provides 
further evidence of efficacy. We found no trend for a 
change in pregnancy risk across 13 cycles, confirming 
that a single vaginal system delivers consistent 
contraceptive efficacy for a full year.
Pearl Indices were variable among subgroups. 
Participants removing the contraceptive vaginal system 
for longer than 2 h during cyclical use had a higher 
Pearl Index (5·89, 95% CI 3·46–9·27) than did women 
who used it properly (2·10, 1·37–3·06), indicative of 
reduced efficacy. The higher Pearl Index in women who 









Pregnancy (failure) No pregnancy (survival) No pregnancy (95% CI)† (survival) Pregnancy (failure)
1 2265 2 143 0·0009 0·9991 0·9987 (0·9959–0·9996) 0·0013
2 2119 7 94 0·0033 0·9967 0·9954 (0·9914–0·9975) 0·0046
3 2018 5 122 0·0025 0·9975 0·9929 (0·9883–0·9957) 0·0071
4 1891 2 76 0·0005 0·9995 0·9924 (0·9876–0·9953) 0·0076
5 1814 4 69 0·0022 0·9978 0·9902 (0·9848–0·9937) 0·0098
6 1741 2 119 0·0011 0·9989 0·9891 (0·9834–0·9928) 0·0109
7 1620 0 76 0·0000 1·0000 0·9891 (0·9834–0·9928) 0·0109
8 1544 3 134 0·0019 0·9981 0·9871 (0·9810–0·9913) 0·0129
9 1407 3 138 0·0021 0·9979 0·9850 (0·9783–0·9897) 0·0150
10 1266 5 126 0·0032 0·9968 0·9819 (0·9744–0·9873) 0·0181
11 1136 3 100 0·0026 0·9974 0·9793 (0·9711–0·9852) 0·0207
12 1033 3 64 0·0029 0·9971 0·9765 (0·9675–0·9830) 0·0235
13 966 2 964 0·0021 0·9979 0·9745 (0·9649–0·9814) 0·0255
*Only pregnancies occurring within 7 days of last contraceptive vaginal system use were included. †The 95% CI was calculated with complementary log-log transformation.
Table 4: Kaplan-Meier intention-to-treat life table analysis of pregnancy
Figure 2: Cumulative probability of no pregnancy
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removed the contraceptive vaginal system for longer 
than 2 h during ring-in days of cyclic use was likely due 
to segesterone acetate serum levels inadequate for 
ovulation suppression,11 and might suggest escape 
ovulation. Although the risk of escape ovulation has 
been described for oral contraceptives with peak–
trough pharmacokinetics,19 further pharma cokinetic 
research is required to uncover whether this 
phenomenon might also occur with steady-state contra-
ceptives (ie, injectables, implants, patches, and vaginal 
rings). Similar to findings from other investigations, 
the youngest participants in our study had the highest 
contraceptive failure rates.20,21 The higher pregnancy 
rate at US versus European sites is also consistent with 
results from other contraceptive studies,22,23 and might 
reflect regional differences in following instructions 
for contraceptive use.
Our post-hoc regression analysis indicated higher 
pregnancy rates for black and Hispanic women desiring 
pregnancy after the study. This finding reflects the 
conclusions of other investigators who have considered 
ethnicity, race, poverty level, and education relative to 
adherence in contraceptive clinical trials.24–26 One 
interpretation is that social and cultural challenges might 
affect adherence and reporting of contraceptive use, 
especially for black and Hispanic women considering 
future pregnancy.27 Based on new research findings of 
greater reported happiness among newly pregnant 
Hispanic and black women compared with white 
women,28 some women might have been considering 
pregnancy even though enrolled in a contraceptive trial 
or they might have been more accepting of unintended 
pregnancy. Overall, factors affecting adherence in clinical 
trials among various populations are complex and 
require further research.
Some aspects of contraceptive adherence might be 
specific to vaginal rings. Results of an acceptability 
study with women in our international study revealed 
that women who removed the contraceptive vaginal 
system for longer than 2 h did so primarily to wash the 
contraceptive vaginal system or for intercourse.29 These 
women were more likely to be black or Hispanic and 
more likely to become pregnant (OR 4·07, 95% CI 
1·58–10·50).29 This finding requires additional research, 
but is important to consider for counselling.
Our results also raise the methodological issue of 
obtaining accurate reports about contraceptive use 
during clinical trials and in real-life settings. Women in 
these trials used paper diaries to record information 
required for calculating pregnancy rates, which did not 
reveal between-group differences in adherence and 
highlight the challenges that investigators must confront 
when trying to show product efficacy in clinical trials.24–27 
Investigators need more innovative technologies and 
strategies for obtaining accurate information about 
participant motivation and behaviours in contraceptive 
trials, especially for user-controlled methods.
The strengths of this efficacy analysis are its large 
sample size, the two-study, multicentre, multicountry 
participant population, the frequency of pregnancy 
testing, and the ongoing follow-up and surveillance. 
Although 962 (42%) patients discontinued the study, 
this was expected, was taken into account when 
determining the sample size, and was similar to reports 
from other contraceptive clinical trials and real-world 
settings.30 A limitation of the study is possible under-
reporting or inaccuracies in the participant-completed 
paper diaries for the use of the contraceptive vaginal 
system and back-up contraception. Another important 
limitation relates to the DSMB decision to limit 
enrolment of and discontinue from the study women 
with a BMI greater than 29·0 kg/m², which might 
influence the generalisability of the data such that 
additional research is warranted. Similarly, studies with 
women from sub-Saharan African and south Asia might 
be warranted as part of introduction of this contraceptive 
vaginal system in these regions.
We have focused here on the efficacy of the 
segesterone acetate and ethinylestradiol contraceptive 
vaginal system; safety data have been published 
separately.9 Authors reported an adverse event profile, 
including type and incidence, consistent with that of 
other combined hormonal contraceptives. Four venous 
thrombotic events occurred in the 2308 women in 
the safety population, and three of these women 
had thrombosis risk factors.9 Thus, women with 
known risk factors for venous thrombotic events (eg, 
BMI >29·0 kg/m², first degree relative with venous 
thrombotic event, or thrombophilia) might not be 
eligible for this contraceptive vaginal system, as their 
pre-existing risk could be enhanced by ethinylestradiol 
use. Additionally, the bleeding pattern observed with 
the segesterone acetate and ethinylestradiol contra-
ceptive vaginal system was consistent with a planned 
hormonal withdrawal bleed during the 7-day ring-
out period, with few women having unscheduled 
(breakthrough) bleeding per cycle.
The segesterone acetate and ethinylestradiol contra-
ceptive vaginal system represents a new contra ceptive 
category recently approved by the FDA as Annovera 
(TherapeuticsMD; Boca Raton, FL, USA). It is a highly 
effective, procedure-free, and woman-controlled contra-
ceptive that can be used cyclically for one year. Women 
and health-care professionals in low-resource settings 
should find the absence of need for refrigeration 
advantageous. Importantly, this novel 13-cycle contra-
ceptive is another birth control option that might help 
address the persistent, unmet, global, contraceptive 
need.
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